Kintor Pharma (HKEX:9939)

Executive Summary

Kintor Pharma is a China-based biopharmaceutical company specializing in innovative therapies for dermatology and oncology, with a core focus on the androgen receptor (AR) pathway. Its pipeline includes KX-826, a topical AR antagonist for androgenetic alopecia currently in Phase 3 trials in China, and GT20029, a topical AR-PROTAC degrader for acne in Phase 2. In oncology, the company is advancing GT0918 for prostate cancer (Phase 1/2) and an ALK-1 antibody for liver cancer (Phase 1). Kintor's expertise in AR-related diseases positions it to address large unmet needs in hair loss and dermatological conditions, with a growing emphasis on novel mechanisms like PROTAC technology. Despite competitive markets, Kintor's strategic focus on China and expanding pipeline offer significant upside. Upcoming milestones include Phase 3 data for KX-826 in alopecia, Phase 2 results for GT20029 in acne, and potential progress with GT0918 in prostate cancer. However, clinical and regulatory risks remain, particularly for the alopecia asset, which must demonstrate meaningful efficacy. Overall, Kintor's valuation hinges on these readouts, and successful outcomes could drive substantial re-rating.

Upcoming Catalysts (preview)

• Q3 2026KX-826 Phase 3 Topline Results for Androgenetic Alopecia60% success
• Q4 2026GT20029 Phase 2 Data for Acne Vulgaris55% success
• H1 2027GT0918 Phase 1/2 Interim Data in Prostate Cancer40% success